Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Revenue
Operating expenses:
General and administrative (including stock-based compensation (Note 7))	291,682	387,526	594,559	707,754
Depreciation	207	347	414	694
Research and development (including stock-based compensation (Note 7))	155,385	114,454	246,373	237,779
Total operating expenses	447,274	502,327	841,346	946,227
Loss from operations	(447,274)	(502,327)	(841,346)	(946,227)
Other expense:
Interest expense	303,171	142,738	407,511	260,340
Total other expense	303,171	142,738	407,511	260,340
Net loss	(750,445)	(645,065)	(1,248,857)	(1,206,567)
Net loss attributable to the noncontrolling interest	524	768	1,039	1,273
Net loss applicable to Bion's common stockholders	$ (749,921)	$ (644,297)	$ (1,247,818)	$ (1,205,294)
Net loss applicable to Bion's common stockholders per basic and diluted common share (in dollars per share)	$ (0.02)	$ (0.02)	$ (0.04)	$ (0.04)
Weighted-average number of common shares outstanding:
Basic and diluted (in shares)	31,187,645	28,804,007	30,990,639	28,135,409